Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (DE:AX9)
FRANKFURT:AX9
Holding DE:AX9?
Track your performance easily
AX9 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.74 - €2.85
Previous Close€1.17
Volume0.00
Average Volume (3M)N/A
Market Cap
€257.20M
Enterprise Value€261.61M
Total Cash (Recent Filing)$39.50M
Total Debt (Recent Filing)$44.33M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Nov 07, 2024EPS Estimate
-€0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding210,288,210
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-7.35
Price to Sales (P/S)1.60
Price to Cash Flow (P/CF)-7.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.50
Enterprise Value/Gross Profit2.17
Enterprise Value/Ebitda-32.47
Forecast
1Y Price Target
€5.77Price Target Upside391.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Akebia Therapeutics News
PremiumPre-Earnings
Is AKBA a Buy, Before Earnings?
PremiumCompany Announcements
Akebia Therapeutics Ends Licensing Deal, Commits to Repayment PlanBulls Say, Bears Say
Bulls Say
Market ReadinessAkebia is well-prepared for a successful launch with rapid uptake and adoption of Vafseo by dialysis organizations.
Regulatory MilestonesThe CMS has granted TDAPA designation for Vafseo, making it eligible to receive additional reimbursement on top of the ESRD bundled rate for two years starting 1/1/2025.
Strategic PartnershipsAkebia entered a multi-year commercial supply contract with US Renal Care, the fastest-growing kidney care provider in the US.
Bears Say
Commercial PotentialA smaller than anticipated commercial opportunity may arise due to market size, competition, and/or pricing challenges.
Market CompetitionThere is a risk of a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing.
Regulatory RisksFailure to secure TDAPA designation for Vafseo and additional regulatory requirements could represent significant timeline delays.
---
Options Prices
Currently, No data available
---
Ownership Overview
11.71% Insiders
6.84% Mutual Funds
0.17% Other Institutional Investors
72.09% Public Companies and
Individual Investors
AX9 FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was €0.74 and its highest was €2.85 in the past 12 months.
What is Akebia Therapeutics’s market cap?
Currently, no data Available
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is in 19 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on Aug 08, 2024. The company reported -€0.037 earnings per share for the quarter, beating the consensus estimate of -€0.066 by €0.029.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -€0.06.
How many shares outstanding does Akebia Therapeutics have?
Akebia Therapeutics has 210,288,210 shares outstanding.
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of -€0.037 in its last earnings report, beating expectations of -€0.066. Following the earnings report the stock price went down -10.866%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Among the largest hedge funds holding Akebia Therapeutics’s share is Graham Capital Management, L.P.. It holds Akebia Therapeutics’s shares valued at 59K.
---
Akebia Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.77 (391.77% Upside)
€5.77 (391.77% Upside)
Blogger Sentiment
Neutral
DE:AX9 Sentiment 50%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
46.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.21%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
---
AX9 Earnings Call
Q2 2024
0:00 / 0:00
---
AX9 Stock 12 Month Forecast
Average Price Target
€5.77
▲(391.77% Upside)
Technical Analysis
Akebia Therapeutics
―
Amneal Pharmaceuticals
―
Corcept Therapeutics
―
Karyopharm Therapeutics
―
Atea Pharmaceuticals
―
Best Analysts Covering AX9
1 Year
1 Year Success Rate
6/16 ratings generated profit
1 Year Average Return
-23.08%
reiterated a buy rating 12 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -23.08% per trade.
---